Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

• Published in: Emerging microbes & infections Vol. 9; no. 1; pp. 757 - 760
• Main Authors: Meng, Juan, Xiao, Guohui, Zhang, Juanjuan, He, Xing, Ou, Min, Bi, Jing, Yang, Rongqing, Di, Wencheng, Wang, Zhaoqin, Li, Zigang, Gao, Hong, Liu, Lei, Zhang, Guoliang
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2020; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Aged; Angiotensin II Type 1 Receptor Blockers - therapeutic use; angiotensin II type1 receptor blockers; angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive Agents - therapeutic use; Betacoronavirus; C-Reactive Protein - analysis; CD3 Complex; CD8-Positive T-Lymphocytes - cytology; China; Clinical outcomes; Coronavirus Infections - complications; Coronavirus Infections - drug therapy; Coronaviruses; COVID-19; Diuretics; Female; Humans; Hypertension; Hypertension - complications; Hypertension - drug therapy; Hypertension - virology; Interleukin-6 - blood; Letter; Male; Middle Aged; Pandemics; Pneumonia, Viral - complications; Pneumonia, Viral - drug therapy; Renin-Angiotensin System; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Viral Load; China; COVID-19; angiotensin-converting enzyme inhibitors; angiotensin II type1 receptor blockers; Renin-angiotensin system; hypertension

The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes...